Alkermes plc Stock
Alkermes plc Stock
There is no change in the price for Alkermes plc today.
Alkermes plc is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a very positive potential of 59.66% compared to the current price of 23.8 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 0.000% | -2.459% | -4.800% | -17.931% | -15.000% | 1.623% | 36.000% |
| Icon plc | -0.200% | -3.870% | 12.856% | -21.161% | -25.669% | -13.701% | - |
| Novocure Ltd | 2.000% | -7.250% | 7.700% | -65.719% | -63.977% | -85.051% | -92.101% |
| Ironwood Pharmaceuticals | -4.050% | -2.632% | 12.121% | -11.905% | -29.524% | -73.948% | -69.485% |
Comments
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Wells Fargo & Company from $42.00 to $37.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $55.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus
